Wells Fargo & Company Vaxcyte, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 47,018 shares of PCVX stock, worth $4.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,018

Previous 49,292 4.61%

Holding current value

$4.07 Million

Previous $3.72 Million 44.22%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$70.52 - $117.12 $160,362 - $266,330	-2,274 Reduced 4.61%	47,018 $5.37 Million
Q2 2024 Aug 13, 2024	BUY	$60.06 - $78.77 $374,594 - $491,288	6,237 Added 14.49%	49,292 $3.72 Million
Q1 2024 May 10, 2024	BUY	$59.79 - $81.05 $432,999 - $586,964	7,242 Added 20.22%	43,055 $2.94 Million
Q4 2023 Feb 09, 2024	SELL	$45.35 - $63.41 $1.12 Million - $1.56 Million	-24,595 Reduced 40.71%	35,813 $2.25 Million
Q3 2023 Nov 13, 2023	SELL	$46.0 - $53.1 $817,972 - $944,224	-17,782 Reduced 22.74%	60,408 $3.08 Million
Q2 2023 Aug 15, 2023	BUY	$34.66 - $54.07 $911,003 - $1.42 Million	26,284 Added 50.64%	78,190 $3.9 Million
Q1 2023 May 12, 2023	BUY	$36.27 - $47.2 $1.74 Million - $2.26 Million	47,945 Added 1210.43%	51,906 $1.95 Million
Q4 2022 Feb 13, 2023	BUY	$20.58 - $47.95 $50,462 - $117,573	2,452 Added 162.49%	3,961 $189,000
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $8,177 - $10,755	-377 Reduced 19.99%	1,509 $36,000
Q2 2022 Aug 12, 2022	SELL	$17.68 - $26.58 $36,473 - $54,834	-2,063 Reduced 52.24%	1,886 $41,000
Q1 2022 May 16, 2022	SELL	$17.46 - $26.36 $242,868 - $366,667	-13,910 Reduced 77.89%	3,949 $95,000
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $339,568 - $464,885	17,576 Added 6210.6%	17,859 $425,000
Q3 2021 Nov 15, 2021	SELL	$20.26 - $26.97 $2,532 - $3,371	-125 Reduced 30.64%	283 $7,000
Q2 2021 Aug 16, 2021	SELL	$16.45 - $24.06 $556,733 - $814,286	-33,844 Reduced 98.81%	408 $9,000
Q1 2021 May 13, 2021	SELL	$18.66 - $29.16 $27,411 - $42,836	-1,469 Reduced 4.11%	34,252 $676,000
Q4 2020 Feb 09, 2021	BUY	$26.57 - $51.74 $582,520 - $1.13 Million	21,924 Added 158.9%	35,721 $949,000
Q3 2020 Nov 05, 2020	BUY	$26.5 - $55.4 $365,620 - $764,353	13,797 New	13,797 $681,000

Others Institutions Holding PCVX

# of Institutions

353

Shares Held

122M

Call Options Held

775K

Put Options Held

433K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.13B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Vaxcyte, Inc. Transaction History